SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 http://www.symbiopharma.com/

March 17, 2010

SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

NDA Submission for Bendamustine HCl (SyB L-0501) in Taiwan

TOKYO, Japan, March 17, 2010 -- SymBio Pharmaceuticals Limited ("SymBio") today announced that InnoPharmax Inc. submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for bendamustine HCl on February 6, 2010, to treat patients with indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). InnoPharmax executed a license agreement with SymBio (March, 2008) for the exclusive right to develop and commercialize bendamustine in Taiwan.

Bendamustine was approved in Hong Kong by the Department of Health (DH) on December 30, 2009, and in Singapore by the Health Sciences Authority (HSA) on January 20, 2010, for use in patients with indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In Japan, SymBio submitted a New Drug Application (NDA) for bendamustine to the Pharmaceuticals and Medical Devices Agency (PMDA) under priority review on October 30, 2009, after receiving orphan drug designation for refractory and relapsed indolent NHL, and mantle cell lymphoma.
SymBio is working closely with its valued partners in Asia Pacific to expand the availability of bendamustine for the treatment of oncology patients throughout the region as expeditiously as possible.

[SyB L-0501]
SymBio holds an exclusive right to SyB L-0501, the company's first drug candidate, from Astellas Deutschland GmbH ("Astellas") for development and commercialization in Japan, China (HK), Taiwan, Korea and Singapore. SymBio and Eisai have executed license agreements for co-development and commercialization of SyB L-0501 in Japan (August, 2008), and exclusive development and commercialization of bendamustine in Korea and Singapore (May, 2009). Cephalon, Inc., which holds the right to bendamustine in North America, has signed a license agreement with SymBio for the development and commercialization right to China (March, 2009). The drug is currently on the market for the treatment of patients with indolent NHL and CLL in the U.S., and is listed as first line therapy for indolent NHL and mantle cell lymphoma in the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology, the recognized standard for clinical policy in oncology. Mundipharma International Corp. Ltd. holds the right to bendamustine in Europe.

[InnoPharmax Inc.]
Established in 2005, InnoPharmax's Research and Development group works on the development of novel delivery vehicles to improve drug *in-vivo* performance, and is fully dedicated to conducting clinical research for new drugs in oncology and immunology with the aim of bringing clinical benefits to patients suffering from unmet medical needs.

[Company Profile]
SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Ltd., and President of Amgen Japan (now Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need," as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs in oncology, hematology, and autoimmune disease.

[Contact]
SymBio Pharmaceuticals Limited.
Hiroki Maekawa,
Corporate Officer,
Head of Corporate Division
Tel: +081(0)3 5472 1125
URL: http://www.symbiopharma.com/